Latest News and Press Releases

REHOVOT, Israel, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the...

Second Quarter 2021 Revenues were $24.2 MillionIn Connection with the Transition of GLASSIA® Manufacturing, Kamada Largely Completed a Workforce Downsizing in the Second Quarter that will Result in an...

REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the...

Label Expansion Differentiates KEDRAB® as the First and Only Human Rabies Immune Globulin (HRIG) Available in the U.S. to be Clinically Studied in ChildrenKEDRAB Product Label Now Includes Patients of...

First Quarter 2021 Revenues were $24.9 Million, and Adjusted EBITDA was $3.7 MillionIn Connection with the Transition of GLASSIA® Manufacturing, the Product’s U.S. Biologics License Application will...

REHOVOT, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the...

Following the Completion of the Transition of GLASSIA Manufacturing, Kamada will Transfer the Product’s US Biologics License Application (BLA) to Takeda; Expected to Occur by End of 2021Kamada to...

As Previously Reported, 11 of the 12 Patients Recovered and were Discharged from Hospital; Seven Patients were Discharged at or Before Day 5 and the Remaining Four Patients were Discharged by Day 9 of...

REHOVOT, Israel, March 09, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived biopharmaceutical company, announced today that Amir London, Chief Executive Officer, will...

Transaction Furthers Kamada’s Strategic Objective to Evolve into a Fully Integrated Specialty Plasma Company Kamada is Already Actively Engaged in the Expansion of the Center’s Collection Capacity;...